Retatrutide product description — Triple hormone receptor agonist peptide
Research Peptide · Triple Agonist · LY3437943
Retatrutide
An investigational once-weekly triple hormone receptor agonist activating GLP-1, GIP, and Glucagon receptors simultaneously. The highest weight reduction reported in the incretin class. Purity >99% · Double lab tested.
Regulatory status
Not yet FDA approved. Under active Phase 3 clinical investigation (TRIUMPH program). NDA submission expected after 2026 trial readouts — earliest plausible approval window is 2027.
Developer
Eli Lilly · Code: LY3437943
Program
TRIUMPH Phase 3
Phase 3 readouts
Through 2026
Dosing
Once-weekly subcutaneous
Mechanism of action — triple receptor
GLP-1 receptor
Insulin & appetite control
Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite centrally — the same broad effects as semaglutide.
Insulin & appetite control
Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite centrally — the same broad effects as semaglutide.
GIP receptor
Augmented glucose control
Amplifies glucose-dependent insulin release; also influences adipose tissue and central pathways relevant to body weight regulation.
Augmented glucose control
Amplifies glucose-dependent insulin release; also influences adipose tissue and central pathways relevant to body weight regulation.
Glucagon receptor
Energy expenditure & lipolysis
Raises basal energy expenditure and promotes lipolysis — the key differentiator from dual agonists like tirzepatide, driving superior weight loss.
Energy expenditure & lipolysis
Raises basal energy expenditure and promotes lipolysis — the key differentiator from dual agonists like tirzepatide, driving superior weight loss.
Clinical trial evidence
Phase 2 — Obesity (NEJM, 2023)
Participants on 12 mg weekly dose at 48 weeks — the highest weight reduction reported for any agent in the GLP-1 class at the time.
24.2% body weight loss
12 mg weekly · 48 weeks
12 mg weekly · 48 weeks
TRIUMPH-4 — Knee Osteoarthritis (Dec 2025)
Phase 3 readout in adults with obesity/overweight and knee osteoarthritis. Showed substantial reductions in both body weight and osteoarthritis pain scores.
~28.7% weight loss
Significant pain reduction
Significant pain reduction
Phase 3 — Type 2 Diabetes (Mar 2026)
Demonstrated significant reductions in HbA1c and body weight in adults with type 2 diabetes.
HbA1c reduction
Significant weight loss
Significant weight loss
Ongoing TRIUMPH studies
Active trials in obstructive sleep apnea, chronic low back pain, cardiovascular & renal outcomes, and metabolic liver disease (MASLD).
Adverse effects & safety
Adverse-effect profile is broadly consistent with the GLP-1 class — gastrointestinal symptoms predominate, particularly during dose escalation: nausea, vomiting, diarrhea, and constipation.
Notable signal: dysesthesia (skin tingling, sensitivity, altered tactile sensation) — reported in ~21% of TRIUMPH-4 participants on the 12 mg dose. Most events were mild; further characterization is ongoing in Phase 3. Cardiovascular and pancreatic safety will be evaluated through the full Phase 3 dataset.




Reviews
There are no reviews yet.